Expert opinion on the prescription practice of dual combination oral anti-diabetic drugs in type 2 diabetes mellitus management

Manjula S.; Krishna Kumar M.

doi:10.18203/2320-6012.ijrms20241894

Authors

Manjula S. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
Krishna Kumar M. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241894

Keywords:

Type 2 diabetes mellitus, Oral anti-diabetic drugs, Dipeptidyl peptidase-4 inhibitors, Sulfonylureas, Metformin

Abstract

Background: This study aimed to gather the clinicians’ perspective regarding the use and prescription practice of dual combination oral anti-diabetic drugs (OADs) in type 2 diabetes mellitus (T2DM) management in Indian settings.

Methods: A cross-sectional study was conducted by using a 29-item structured questionnaire covering factors considered, challenges, preferred indicators of glycemic control, continuous glucose monitoring (CGM) use, and strategies. Additionally, it explored clinicians' feedback and experiences with dual combination oral anti-diabetic drugs in T2DM management.

Results: Seventy percent of clinicians observed improved adherence to dual combination therapy of OAD. The combination of dipeptidyl-peptidase 4 (DPP4) inhibitors and metformin was favored for early initiation and showed better tolerability within the first year according to 42% of clinicians. Approximately 63% of clinicians prefer vildagliptin + metformin for 40–50 year-old diabetics. The combination yields favorable outcomes: 21% in young, 14% in elderly, and 7% in long-standing diabetes cases. After 5 years, 37% of clinicians observed 40-50% of diabetics reaching an HbA1c goal of <7.0% with this combination. Clinicians choose glimepiride + metformin for treatment intensification based on its efficacy, cardiovascular (CV) safety, and fewer adverse events. These factors were collectively recognized by 66.54% of respondents.

Conclusions: This study provided valuable insights into real-world clinical practices and preferences regarding dual combination therapy for diabetes management. Clinicians identified the fixed-dose combination of DPP4 inhibitors and metformin as the preferred choice and highlighted the effectiveness of glimepiride + metformin in overcoming treatment intensification challenges.

Metrics

Metrics Loading ...

References

Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabet Endocrinol. 2023;11(7):474-89.

World health Organization. Diabetes - India. Available at: https://www.who.int/india/health-topics/mobile-technology-for-preventing-ncds. Accessed 15 March 2024.

IDF Diabetes Atlas. Diabetes around the world in 2021. Available at: https://diabetesatlas.org/. Accessed 15 March 2024.

Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-12.

Piragine E, Petri D, Martelli A, Calderone V, Lucenteforte E. Adherence to oral antidiabetic drugs in patients with type 2 diabetes: systematic review and meta-analysis. J Clin Med. 2023;12(5):1981.

Kalra S, Das AK, Priya G, Ghosh S, Mehrotra RN, Das S, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care. 2020;9(11):5450-7.

Ahrén B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag. 2008;4(2):383-94.

Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17(10):1100-9.

UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care. 1998;21(1):87-92.

Cheng W, Pan Y, Xu Q. Combined use of dipeptidyl peptidase-4 inhibitors and metformin reduces blood sugar level and improves pancreatic islet β cell function in the treatment of type 2 diabetes mellitus: A meta-analysis. Int J Clin Exp Med. 2016;9(11):20624-32.

Das S, Gupta A, Bandyopadhyaya B, Darla BH, Arya V, Abhyankar M, et al. Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management. Bioinformation. 2021;17(3):413-23.

Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519-29.

Ding Y, Liu Y, Qu Y, Lin M, Dong F, Li Y, et al. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(8):2802-17.

Mohan V, Zargar A, Chawla M, Joshi A, Ayyagari U, Sethi B, et al. Efficacy of a combination of metformin and vildagliptin in comparison to metformin alone in type 2 diabetes mellitus: a multicentre, retrospective, real-world evidence study. DMSO. 2021;14:2925-33.

Ionova T, Nikitina T, Kurbatova K, Rodionova A. Benefits and risks of vildagliptin/metformin versus sulphonylureas/metformin combination therapy in Type 2 Diabetes Mellitus (T2dm) from patient’s perspective: real-world data. Value in Health. 2015;18(7):A615.

Chawla M, Kim TH, Mirasol RC, Faruque P, Cooke K, Hours-Zesiger P, et al. Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia. Curr Medi Res Opin. 2018;34(9):1605-11.

El Ebrashy I, El Kafrawy N, Raouf R, Yousry D. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. Diab Res Clin Pract. 2020;162:108042.

Filozof C, Schwartz S, Foley JE. Effect of vildagliptin as add-on therapy to a low-dose metformin. World J Diab. 2010;1(1):19-26.

Miller JL, Salman K, Shulman LH, Rose LI. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes. Clin Pharmacol Ther. 1993;53(3):380-4.

Sahay RK, Mittal V, Gopal GR, Kota S, Goyal G, Abhyankar M, et al. Glimepiride and metformin combinations in diabetes comorbidities and complications: real-world evidence. Cureus. 2020;12(9):e10700.

Kim H soon, Kim D man, Cha B soo, Park TS, Kim K ah, Kim D lim, et al. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014;5(6):701-8.

Kumar KP, Seshadri K, Aravind SR, Deb P, Modi KD, Gopal RA, et al. Real-world observational study of glimepiride and metformin fixed-dose combination along with insulin in the management of type 2 diabetes mellitus: Indian experience. Cureus. 2021;13(1):e13020.

Kumar S. Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 Diabetic patients. Ind J Endocrinol Meta. 2021;25(4):326-31.

Park CY, Kang JG, Chon S, Noh J, Oh SJ, Lee CB, et al. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. PLoS One. 2014;9(3):e87799.

Jain P, Kasliwal R, Singh SK, Shah A, Bhardwaj VK, Chordia J, et al. Usage of low-dose glimepiride (0.5 mg) and metformin combination in the management of type 2 diabetes continuum in Indian setting. Asian J Diabetol. 2022;23(3):8-19.